目的：观察美沙拉嗪联合双歧杆菌四联活菌治疗活动期溃疡性结肠炎（UC）的疗效和安全性。方法：83 例活动期UC患

者随机分为对照组（42 例）和试验组（41 例）。对照组患者给予美沙拉嗪肠溶片1.0 g，口服，每日4 次；试验组患者在对照组治疗的

基础上给予双歧杆菌四联活菌片1.5 g，口服，每日3 次。两组患者疗程均为6 周。观察两组患者临床疗效，治疗前后血清超敏C反

应蛋白（hs-CRP）、白介素（IL）-4、IL-8 水平及不良反应发生情况。结果：治疗后，两组患者血清hs-CRP、IL-8 水平均显著低于同组

治疗前，且试验组低于对照组，IL-4 水平显著高于同组治疗前，且试验组高于对照组，差异均有统计学意义（P＜0.05 或P＜0.01）。

试验组患者总有效率显著高于对照组，差异有统计学意义（P＜0.05）。两组患者不良反应发生率比较，差异无统计学意义（P＞

0.05）。结论：美沙拉嗪联合双歧杆菌四联活菌治疗活动期UC的疗效显著优于单用美沙拉嗪，且安全性相当。

OBJECTIVE：To observe the efficacy and safety of mesalazine combined with bifidobacterium tetravaccine（live）in the

treatment of ulcerative colitis（UC）. METHODS：83 UC patients were tandomly divided into control group（42 cases）and test group

（41 cases）. Control group was orally given 1.0 g Mesalazine enteric-coated tablet，4 times a day；test group was additionally given 1.5

g Bifidobacterium tetravaccine tablet（live），3 times a day. The treatment course fr both group was 6 weeks. The clinical efficacy，and

serum high sensitivity C-reactive protein（hs-CRP），interleukin（IL）-4，IL-8 levels before and after treatment and the incidence of adverse

reactions in 2 groups were observed. RESULTS：After treatment，serum hs-CRP and IL-8 in 2 groups were significantly lower

than before，and test group was lower than control group；serum IL-4 level was significantly higher than before，and test group was

higher than control group，the differences were statistically significant（P＜0.05 or P＜0.01）. Total effective rate in test group was significantly

higher than control group，the difference was statistically significant（P＜0.05）. And there was no significant difference in

the incidence of adverse reactions（P＞0.05）. CONCLUSIONS：Mesalazine combined with bifidobacterium tetravaccine（live）is

more effective than mesalazine alone UC，with similar safety.